The eŠect of hydrophobic extracts of human and rat urine on in-vitro P-glycoprotein (P-gp) function was examined, in terms of intra-, inter-individual variations, and physiological states. Six urine samples out of 7, obtained from one male subject on diŠerent days, suppressed P-gp function with diŠer-ent potencies. Similarly, 11 samples out of 15 diŠerent individuals (8 males and 7 females) inhibited P-gp function. Among them, urine from one female, obtained 1 month after delivery, showed a potent inhibitory eŠect. Another urine from a pregnant female, obtained 1 week before delivery, showed further potent inhibition on P-gp function. In addition, urine from normal rats strongly inhibited P-gp function at much lower concentrations than human urine, and the inhibitory potencies varied in diseased states; control (without urine extract)＝experimental acute renal failureºexperimental acute hepatic failureºnormal rat urine. When human urine extract was separated by a two-dimensional thin-layer chromatography, several spot fractions inhibited P-gp function, and equilin was identiˆed in one fraction as an endogenous P-gp inhibitor. In conclusion, it was demonstrated that urine contains many endogenous P-gp inhibitors, and their inhibitory potencies on P-gp function vary with intra-and inter-individual variations, and under diŠerent physiological states.
Introduction P-Glycoprotein (P-gp), an ATP-dependent eOEux pump, is expressed in various normal tissues, including the intestine, liver, kidney, eye, brain, and so on. 1, 2) P-gp transports a variety of structurally and pharmacologically unrelated hydrophobic endogenous and exogenous compounds to prevent the entry and W or accumulation of P-gp substrates in tissues. Many clinically important drugs such as immunosuppressive agents, calcium channel blockers, anticancer agents and b-blockers are P-gp substrates, and expression level and W or function of P-gp aŠect their pharmacokinetics and pharmacodynamics. P-gp is now recognized as an important host defense mechanism for a living body, along with a variety of metabolic enzymes.
Recently, we investigated the expression and function of P-gp in rats with glycerol-induced acute renal failure (ARF) and with carbon tetrachloride (CCl4)-induced acute hepatic failure (AHF). 3, 4) In these diseased rats, the in-vivo P-gp function in the liver, kidney and brain was all suppressed, even though the expression level of P-gp remained unchanged, or rather increased in the target intoxicated organs (the kidney of ARF rats and the liver of AHF rats). In Caco-2 cells, the plasma obtained from diseased rats exhibited a greater inhibitory eŠect on P-gp function than did plasma from normal rats. A higher plasma level of corticosterone, an endogenous P-gp substrate W inhibitor, was also observed in these diseased rats. 4, 5) These results suggested that concentrations and W or compositions of endogenous Pgp-related substances in plasma vary under diseased states and such alteration aŠects P-gp function systemically.
In the present study, we evaluated whether human and rat urine, as well as rat plasma, exhibit inhibitory eŠects on P-gp function, based on the assumption that endogenous P-gp substrates W inhibitors are excreted into the urine under normal conditions, and their excretion would be altered under diŠerent physiological states, including intra-and inter-individual variations. Evaluation was made by measuring the inhibitory eŠect of hydrophobic extracts of these biological ‰uids on transepithelial transport or accumulation of a P-gp substrate (rhodamine 123 (Rho123) or [ 3 H] daunorubicin (DNR)) in Caco-2 or LLC-GA5-COL150 cells. Caco-2, a human colonic adenocarcinoma cell line expressing various functions of diŠerentiated intestinal epithelial cells, is a useful in-vitro system for studying the function of P-gp in the intestine. [6] [7] [8] [9] LLC-GA5-COL150 is a transfectant cell line of a porcine kidney epithelial cell line LLC-PK1 with human MDR1 cDNA, which overexpresses human P-gp on the apical membrane. 10, 11) We also attempted to isolate and identify new P-gp inhibitor(s) in human urine extract. Preparation of hydrophobic extracts of biological ‰uids: Bond Elut TM (Varian) was used to prepare hydrophobic extract from human urine. Permission for using urine was obtained from each healthy subject (total 16 subjects, 8 male and 8 female) with written informed consent (except for 2 little girls whose permission was obtained from their mother). Freshly collected 100-mL human urine was applied on a cartridge of Bond Elut TM . After passing urine, the cartridge was washed out with 10-mL distilled water to remove hydrophilic substances. Substances retained in the cartridge were eluted with 1-mL methanol to obtain hydrophobic extract. The solvent was evaporated to dryness under reduced pressure, and the residue was stored at "309 C until use. Prior to experiments, the residue was dissolved with an appropriate amount of dimethylsulfoxide (DMSO). For thin-layer chromatography (TLC) study, human urine was extracted with ethylacetate to obtain a large amount of urine extract, after conˆrming that components of ethylacetate extract, but not of hexane or heptane extract, are close to those extracted with Bond Elut TM in a two-dimensional TLC (described below).
Materials and Methods

Materials
For preparation of rat urine and plasma extracts, male Wistar rats (260-320 g) were used. Experimental acute renal failure (ARF) and acute hepatic failure (AHF) were induced in the same manner as described previously. 3, 4, 12) Brie‰y, ARF was induced by an injection of glycerol dissolved in saline (50z v W v, 10 mL W kg) into the leg muscle after a 24-h period of water deprivation. 3, 12) AHF was induced by an intraperitoneal injection of a mixture of carbon tetrachloride (CCl4) and olive oil (50z v W v) at a dose of 5 mL W kg. 4) These rats were used for experiments 24 h after injection, and freshly collected rat urine and plasma were extracted with ethylacetate. Animal experiments were performed in accordance with the Guide for Animal Experimentation from the Committee of Research Facilities for Laboratory Animal Sciences, Graduate School of Biomedical Sciences, Hiroshima University.
Separation of human urine extract by two-dimensional TLC: Slurry of silica gel (Kieselgel 60 GF254 suspended in distilled water) was spread at a 0.5-mm layer on 20×20-cm plates and allowed to air dry. The plates were activated for 1 h at 1209 C, and DMSO solution of human urine extract prepared from 100-mL urine was applied to the origin of a TLC plate immediately after the plate had been cooled to room temperature. The developing solvents used were a mixture of chloroform and acetone (2:1, v W v) for theˆrst dimension and a mixture of chloroform and methanol (97:3, v W v) for the second dimension. Urine components separated on the plate were detected by UV lamp, and each spot was carefully scraped oŠ into a tube. The silica gel containing urine component(s) was re-extracted with a su‹cient amount of ethylacetate, and the solvent was evaporated, then the residue was dissolved in DMSO. These separated components of human urine extract by TLC were subjected to the study of the inhibitory eŠect on P-gp function or isolation W identiˆcation of new endogenous P-gp inhibitor(s).
Isolation and identiˆcation of endogenous P-gp inhibitor(s): Several spots observed in a two-dimensional TLC for human urine extract were further separated and identiˆed by gas chromatography-mass spectrometry (GC-MS). GC-MS used was Hewlett Packard Model 5890 Series II gas chromatograph interfaced to a Hewlett Packard Model 5971 mass selective detector (Palo Alto, CA, USA). The capillary column used was HP-1 (0.25 mm×30 m, Hewlett Packard), and column temperature was adjusted at 709 C (2-min hold) and increased by 159 C W min up to 2709 C. Injection and detection temperatures were 2509 C and 2809 C, respectively.
Cell culture: Cells were cultured on Transwell TM cell culture chambers (Costar, Cambridge, MA). Caco-2 cells were cultured with DMEM containing 10z FBS, 1z nonessential amino acids, 2 mM L-glutamine, 100 units W mL penicillin G and 100 mg W mL streptomycin in an atmosphere of 5z CO2-95z air at 379 C. 9, 13) Fresh medium was replaced every 2 days. The passages of cells used were between 67 and 86. LLC-GA5-COL150 cells were cultured with Medium 199 containing 10z FBS, 100 U W mL penicillin, 100 mg W mL streptomycin and 150 ng W mL colchicine in an atmosphere of 5z CO2-95z air at 379 C. 10, 11) Fresh medium was replaced every 2 days. Prior to the transport and W or accumulation studies, cells were incubated for 6 hrs with fresh Medium 199 to remove colchicine. The passages of cells used were between 7 to 24.
Transport and accumulation studies in vitro: Transepithelial transport and accumulation of Rho123 or [
3 H]DNR in Caco-2 or LLC-GA5-COL150 cells were measured in Transwell TM chamber at 379 C in the same manner as reported previously. 9, 13) Caco-2 cells were used at 16-21 days and LLC-GA5-COL150 cells at 5-7 days after seeding. Rho123 or [
3 H]DNR was dissolved in Hank's balanced salt solution containing 25 mM HEPES, 25 mM glucose (HBSS, pH 7.4) and 0.5z DMSO at concentrations of 5 mM or 100 nM, respectively, and was placed either on the apical (1.5 mL) or basolateral (2.6 mL) side of cells. The other side waŝ lled with HBSS containing 0.5z DMSO in control study. In inhibition study, urine extract, plasma extract, or verapamil (a P-gp inhibitor) was added to both sides to give a designatedˆnal concentration with 0.5z DMSO. In studies with 17b-estradiol, equillin, estriol and estrone, the concentration of DMSO in the medium was adjusted at 2z. After incubation for a designated period of time, the medium on the other side was periodically collected, and the concentration of a P-gp substrate was determined as described below. After transport study, the chamber was washed with a su‹cient amount of ice-cold HBSS, and the cell monolayers were separated together with its support (polycarbonate membraneˆlter) to determine the accumulation of the substrate in cells. Cell monolayers were incubated in 0.5z trichloroacetic acid solution to release Rho123 or in 0.1 M NaOH to release [ 3 H]DNR.
Analyses of Rho123 and [ 3 H]DNR:
The concentration of Rho123 in aqueous samples was determined by ‰uorescence spectrophotometer (Hitachi F-3000, Tokyo, Japan) at wavelengths of 485 nm for excitation and 546 nm for emission.
13) The radioactivity of the col- 9, 13) and theseˆndings, evaluation of biological-‰uid extracts as P-gp inhibitors was carried out by measuring their eŠects on the transepithelial transport of Rho123 across Caco-2 cell monolayers or the accumulation of [ 3 H]DNR in LLC-GA5-COL150 cells.
Inhibitory potency of human urine extract on P-gp function: EŠect of hydrophobic human urine extract, collected from a 23-years old male subject, on b-to-a transport of Rho123 across Caco-2 cell monolayers was examined. Urine extract was added in the transport medium at diŠerentˆnal concentrations as follows: ×2.5, 2.5-fold higher concentration of original urine (extract from 2.5-mL human urine W mL of transport medium); ×5, concentrated by 5-fold; ×10, concentrated by 10-fold. With ×2.5 urine extract, the b-to-a transport of Rho123 was not aŠected, but with ×5 and ×10 urine extracts, the b-to-a transport of Rho123 was signiˆcantly suppressed (data not shown). With ×5 urine extract, 6 samples out of 7, collected on diŠerent days (during from December 3rd, 1997 to August 4th, 1998) from the same male subject, suppressed the P-gpmediated eOEux transport of Rho123 in Caco-2 cells (Fig. 1) . These results indicate that human urine con- (1998) . Each value is the mean±S.E. of 3 trials. The value without error bar is the result of 1 trial. Fig. 2 . EŠect of human male (A) and female (B) urine extracts on the basal-to-apical transport of Rho123 across Caco-2 cells. Rho123 (5 mM) was placed at the basal side of monolayers, and human urine extract was added in the transport medium at a 5-fold higher concentration of original urine. The transport study was carried out for 120 min in the absence (control) or presence of urine extract. Each value is the mean±S.E. of 3-11 trials. The value without error bar in Fig. 2B is the result of 1 trial. tains putative P-gp inhibitor(s), but the inhibitory potency on P-gp function may vary day by day.
Similarly, urine extracts were prepared from 15 diŠer-ent individuals (8 males, 7 females), and their inhibitory potencies on P-gp function were compared using ×5 extract ( Fig. 2A and B) . Their inhibitory potencies varied remarkably among diŠerent individuals, and 11 samples out of 15 inhibited the P-gp function. Among them, urine extract of a female (39 years old), obtained 1 month after delivery, showed a greater inhibitory potency than other extracts, and urine extracts of 3 and 5-years old girls showed no inhibitory eŠects (Fig. 2B) .
In a separate experiment, urine from a pregnant female 1 week before delivery was examined in the accumulation study of (Fig. 3) . These results may suggest that urine from a pregnant female has much greater inhibitory eŠect on P-gp function than other extracts.
Inhibitory potencies of rat urine and plasma extracts on P-gp function: Urine and plasma extracts were prepared by ethylacetate extraction from normal, glycerol-induced ARF and CCl4-induced AHF rats, and their eŠects on transport of Rho123 across Caco-2 cell monolayers were examined. As compared with human urine extract, urine extract from normal rats showed P-gp inhibitory eŠect even at a very low concentration (×0.0125, 80-fold dilution). The inhibitory potencies of human urine extract obtained from 100-mL urine of 23-years old male subject was separated by a two-dimensional TLC (see Fig. 5 for each spot number). Rho123 (5 mM) was placed at the basal side of monolayers, and each spot fraction was added in the transport medium. Transport study was carried out for 120 min in the absence (control) or presence of a spot fraction. Each value is the mean±S.E. of 2 trials, except fraction No. 10 (1 trial).
urine and plasma extracts varied depending on their physiological states, in which ARF rat urine extract showed no inhibitory eŠect and the inhibitory potency of AHF rat urine extract was lower than that of normal rats (Fig. 4A) . In contrast to those of urine extracts, the inhibitory potencies of plasma extracts were in reverse order as follows: control (without plasma extract)＝nor-malºAHFºARF rat plasma (Fig. 4B) . These results indicate that P-gp inhibitors are normally excreted into the urine, but they are accumulated in the plasma under diseased states, especially under ARF states.
Separation of human urine extract by a two-dimensional TLC and inhibitory potencies of the components on P-gp function: Human urine was collected from a 23-years old male subject (same person as for Figs. 1 and 2) for several days and combined together. Urine extract was prepared by extracting with ethylacetate, and the extract obtained from 100-mL urine was applied on a 20×20-cm TLC plate to separate their components (Fig. 5) . Some spot fractions were scraped oŠ to collect urine components, and their inhibitory potencies on the b-to-a transport of Rho123 were examined in Caco-2 cells (Fig. 6) . Although the recovered amounts of urine components were diŠerent among diŠerent spot fractions, some fractions (spot No. 1, 2, 6-9, 11) showed inhibitory eŠects on P-gp function.
Isolation and identiˆcation of endogenous P-gp inhibitor(s): Among various spots shown in Fig. 5 , the fraction of spot No. 8 had a relatively large amount of components. Analysis of No. 8 fraction by GC-MS indicated that this spot contains more than 10 diŠerent components and equilin was found within them. Identiˆca-tion was made by comparing with GC-MS spectrum of standard equillin. As well, 3a-hydroxy-5b-androsten-11,17-dion, stearic acid, and adipic acid were found in No. 8 fraction. Since the eŠect of equilin on P-gp function has not yet been reported, the inhibitory eŠect of equilin, together with estriol, estron, and 17b-estradiol (a standard of estrogen), on [ 3 H]DNR accumulation in LLC-GA5-COL150 cells was examined. At a concentration of 100 mM, equilin and estriol, as well as 17b-estradiol, increased the accumulation of [ 3 H]DNR signiˆcantly (Fig. 7) .
Discussion
The inhibitory potencies of hydrophobic extracts pre- pared from human and rat urine on in-vitro P-gp function were evaluated in terms of intra-and inter-individual variations, and from the viewpoints of the eŠects of physiological states. Also, we attempted to isolate and identify new P-gp inhibitor(s) in human urine extract. Regarding human plasma and rat urine, the presence of P-gp inhibitors has already been reported. [14] [15] [16] [17] [18] A number of endogenous and synthetic steroid hormones have also been identiˆed as P-gp substrates W inhibitors. These include aldosterone, corticosterone, cortisol, 17b-estradiol, desoxycorticosterone, predonisolone, progesterone, progesterone metabolites, promegsterone, testosterone, and so on. 11, 15, 18, [19] [20] [21] [22] [23] Among these steroid hormones, cortisol and progesterone are reported to be relatively potent P-gp inhibitors. 18, 21) Recently, we examined the expression and function of P-gp in rats with ARF and AHF, and found that the plasma of ARF and AHF rats showed greater P-gp-inhibitory eŠect than did normal plasma. Also, the concentration of corticosterone in the plasma was approximately 2-fold higher in these diseased rats, as compared with normal rats. 4, 5) Such endogenous P-gp inhibitors in the plasma would be excreted into the urine by glomerularˆltration and by P-gp-mediated secretion at the luminal surface of renal proximal tubules.
In evaluating P-gp-inhibitory eŠect of biological-‰uid extracts, a sensitive evaluation system is prerequisite. For example, in Caco-2 cells, the inhibitory eŠect of verapamil on the eOEux (b-to-a) transport of Rho123 was clearly observed, however, the enhancing eŠect of verapamil on a-to-b transport of Rho123 was small. 9) Also, the eŠect of verapamil on the accumulation of Rho123 in Caco-2 cells was small (data not shown). These results indicate that the inhibitory eŠect of verapamil on P-gp function could be sensitively detected by examining the eŠect on Rho123 eOEux transport, rather than the eŠect on a-to-b transport or accumulation of Rho123 in Caco-2 cells. In contrast to Caco-2 cells, eOEux transport and accumulation of [ 3 H]DNR were found to be more sensitive parameters than those of Rho123, when LLC-GA5-COL150 cells were used. The reason for such diŠerences between cells is not clear at present.
However, similar cases are sometimes observed, and some P-gp substrates were or were not transported in a polarized mode, depending on cell types expressing P-gp. 24) The apparent contribution of P-gp in overall transport process may depend on the characteristics of cell membrane such as permeability (lipoidal barrier function) to a P-gp substrate as well as physicochemical properties of the substrate. Collectively, in the present study, the P-gp-inhibitory eŠects of biological-‰uid extracts were examined mainly by transport studies of Rho123 in Caco-2 cells and partly by accumulation studies of [ 3 H]DNR in LLC-GA5-COL150 cells. In human urine study, the sampling time of urine, the intake amount of water, and meals were not controlled nor restricted, although the intake of P-gp-related drugs was restricted. Therefore, the apparent intra-and interindividual variations of P-gp inhibitory potencies of human urine extracts observed in the present study may partly be derived from such experimental protocols. With ×5 human urine extracts, more than half samples derived from the same or diŠerent individuals showed inhibitory eŠects on in-vitro P-gp function ( Figs. 1 and  2 ). Among these samples, urine obtained from little girls (3 and 6 years old) showed no inhibitory eŠect and a female urine, 1 month after delivery, exhibited the greatest inhibition (Fig. 2B) . Also, in accumulation study of [ 3 H]DNR in LLC-GA5-COL150 cells, the urine from a pregnant female showed P-gp-inhibitory eŠect even at the same concentration of its original urine (Fig. 3) . The greater inhibitory potency of female urine collected before and after deliver may be due to the higher levels of steroid hormones such as estriol and pregnanediol in the urine. 25, 26) Although further study is necessary to clarify the reasons for the diŠerent P-gp inhibitory potencies among diŠerent individuals, the physiological states of hosts such as age, pregnancy and diseases would relate to the P-gp-inhibitory potencies of their urine extracts.
Rat urine extract, as well as rat plasma extract, was analyzed mainly in terms of the eŠect of disease sates. We have already reported the inhibitory eŠect of ARF and AHF rat plasma on P-gp function, although we used the plasma itself without extraction in those studies. 3, 4) Also, it has been found that the plasmaˆltrate of AHF rats, obtained by ultraˆltration using semipermeable cellulose membrane, showed no inhibitory eŠect. 4) These results suggested that endogenous P-gp inhibitors are lipophilic and mostly bound to plasma proteins, as reported elsewhere. 16) Interestingly, among diŠerent physiological states, the rank order of inhibitory potencies was in reverse order between urine and plasma extracts as follows: urine extracts, control (without urine extract)＝ARFºAHFºnormal rat urine extracts; plasma extracts, control (without plasma extract)＝normalºAHFºARF rat plasma extracts (Fig. 4) . These results indicate that endogenous P-gp inhibitors are excreted into the urine under normal conditions, but they are accumulated in the plasma under ARF and AHF states.
Some spot fractions of human urine extract separated by a two-dimensional TLC showed P-gp-inhibitory eŠects (Figs. 5 and 6) . The diŠerent inhibitory potencies among diŠerent spot fractions would depend on the diŠerence in its amount and W or composition of each fraction. Fractions of spot No. 1 and 2 showed relatively strong inhibitory potencies as compared with other fractions (Fig. 6) . However, they are fairly hydrophilic among components in ethylacetate extract as evaluated from their Rf values (Fig. 5) . It is generally accepted that the substrates and W or inhibitors of P-gp are hydrophobic, uncharged or positively charged compounds. Therefore, in the present study, more hydrophobic fractions were examined further. The amounts recovered from spot No. 8, 10 and 11 were relatively large, and No. 8 fraction contained more than 10 components when separated by GC-MS. Also, No. 11 fraction was further separated into more than 8 components by HPLC (data not shown). In No. 8 fraction, equilin was detected, and equilin, as well as estriol, was newly found to be one of endogenous P-gp inhibitors (Fig. 7) . Further study is necessary to isolate and identify other endogenous P-gp inhibitors W substrates in human urine.
In the present study, we examined the P-gp-inhibitory potencies of human and rat urine extracts. Urine is the ‰uid that escaped from tubular reabsorption and about 99z of waterˆltered through glomerulus is normally reabsorbed. 27) Thus, concentrations of endogenous P-gp inhibitors in the ‰uid at proximal renal tubules, where P-gp is expressed, may be much lower than those in the urine, although the extent of reabsorption of endogenous P-gp inhibitors is unclear. When considering the inhibitory potency of urine extract and experimentally employed concentration of extract in the medium, even urine from a pregnant female may not directly inhibit P-gp function at the proximal renal tubules. However, disease states such as kidney dysfunction may markedly increase the risk of systemic P-gp suppression, because the basal levels of P-gp inhibitors in the biological ‰uids would be very high during pregnancy. On the other hand, rat urine extract showed signiˆcant P-gpinhibitory eŠect even at diluted concentrations. It has been reported that the eŠective concentration of the substance in rat urine required to inhibit in-vitro P-gp function was similar and within the range of its urinary concentration. 16) However, our results indicate that Pgp-inhibitory potency of rat urine is greater and it may interfere with P-gp even at proximal renal tubules. The diŠerence of P-gp-inhibitory potencies between human and rat urine extracts may be clariˆed by comparing urine components as well as their concentrations. Also, such investigation may lead to the development of endogenous, safer and potent multidrug resistance-reversing agents.
In conclusion, it was demonstrated that urine contains many endogenous P-gp inhibitors, and their inhibitory potencies on P-gp function vary with intra-and inter-individual variations, and under diŠerent physiological states.
